Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Alm Cdiff FMT WGS data

ABSTRACT: WGS data from FMT trial for the treatment of recurrent Clostridium difficile infection

PROVIDER: PRJEB23524 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR2198620_1.fastq.gz	Fastqsanger.gz
	ERR2198620_2.fastq.gz	Fastqsanger.gz
	ERR2198630_1.fastq.gz	Fastqsanger.gz
	ERR2198630_2.fastq.gz	Fastqsanger.gz
	ERR2198640_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 220

Similar Datasets

Alm Cdiff FMT 16S data

Project description:16S data from FMT trial for the treatment of recurrent Clostridium difficile infection

| PRJEB23489 | ENA

Treatment of rCDI with FMT, WGS data

Project description:Treatment of recurrent Clostridioides difficile infection with Fecal Microbiota Transplantation

| PRJEB39023 | ENA

WGS of Clostridium difficile

Project description:Whole-genome sequencing of Clostridium difficile strains implicated in recurrent infection.

| PRJEB6575 | ENA

FMT datasets

Project description:FMT datasets of patients with recurrent Clostridioides difficile infection (rCDI), inflammatory bowel disease (IBD), and colonization from multi-drug resistant bacteria (MDRB)

| PRJEB47909 | ENA

Project description:EMG produced TPA metagenomics assembly of PRJEB23524 data set (WGS data from FMT trial for the treatment of recurrent Clostridium difficile infection).

| PRJEB44032 | ENA

Intestinal Mucosal Mitochondrial Oxidative Phosphorylation worsens with Cirrhosis Progression and is ameliorated with FMT

Project description:Intestinal barrier dysfunction, driven by increased oxidative phosphorylation (OXPHOS) activity that leads to tissue hypoxia, contributes to the progression of cirrhosis, particularly impacting the upper intestine. This study explores the interplay between intestinal OXPHOS, gut microbiota changes, and the effects of fecal microbiota transplant (FMT) in cirrhotic patients. We investigated 32 age-matched men across three groups: healthy controls, compensated cirrhosis, and decompensated cirrhosis. Each underwent endoscopy with duodenal and ascending colon biopsies. Subsequently, in a follow-up study, nine patients with hepatic encephalopathy, previously enrolled in a randomized controlled trial for FMT capsules, underwent repeat pre and post-FMT upper endoscopy. Our bioinformatics analysis highlighted a significant upregulation of nuclear-encoded OXPHOS genes in both intestinal regions of cirrhosis patients compared to controls, with further dysregulation in the decompensated group. We also observed a strong correlation between shifts in gut microbiota composition, Model for End-Stage Liver Disease (MELD) scores, and OXPHOS activity. Following FMT, patients displayed a significant reduction in OXPHOS gene expression in the duodenum, suggesting that FMT may restore intestinal barrier function and offer a therapeutic avenue to mitigate liver disease progression. The findings indicate that managing intestinal OXPHOS and microbiota through FMT could be relevant in modulating microbially-based therapies.

2024-12-26 | GSE285291 | GEO

FMT improve spleen function

Project description:FMT from AOS treated mice rescue busulfan disrupted spleen

2022-11-03 | GSE160965 | GEO

Tumor and gut biopsies from refractory metastatic melanoma patients before and after treatment with fecal microbiota transplantation (FMT) and anti-PD-1 re-induction (Baruch et al, Science 2020)

Project description:We performed a phase I clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and re-induction of anti-PD-1 immunotherapy in patients with anti-PD-1-refractory metastatic melanoma. FMT donors were two metastatic melanoma patients who achieved a durable complete response. FMT recipient patients were metastatic melanoma patients who failed at least one anti-PD-1 line of treatment. Each recipient patient received FMT implants from only one of the two donors. FMT was conducted by both colonoscopy and oral ingestion of stool capsules, followed by anti-PD-1 re-treatment (Nivolumab, BMS). Recipient patients underwent pre- and post-treatment stool sampling, tissue biopsy of both gut and tumor, and total body imaging. Clinical responses were observed in three patients, including two partial responses and one complete response. Notably, treatment with FMT was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment.

2020-12-31 | GSE162436 | GEO

Human colon epithelial cells treated with Clostridium difficile Toxins A and B

Project description:Toxin A and B from Clostridium difficile are the primary virulence factors in Clostridium difficile disease. The changes in gene transcription of human colon epithelial cells were investigated in vitro in order to better understand the many effects of both toxins.

2012-01-06 | GSE29008 | GEO

FMT for CDI

Project description:Faecal microbiota transplant as treatment for recurrent Clostridioides difficile infection

| PRJEB30298 | ENA